KR101314880B1 - 관절류머티즘 치료제 - Google Patents

관절류머티즘 치료제 Download PDF

Info

Publication number
KR101314880B1
KR101314880B1 KR1020117024354A KR20117024354A KR101314880B1 KR 101314880 B1 KR101314880 B1 KR 101314880B1 KR 1020117024354 A KR1020117024354 A KR 1020117024354A KR 20117024354 A KR20117024354 A KR 20117024354A KR 101314880 B1 KR101314880 B1 KR 101314880B1
Authority
KR
South Korea
Prior art keywords
amino acid
acid sequence
seq
set forth
sequence set
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020117024354A
Other languages
English (en)
Korean (ko)
Other versions
KR20110139734A (ko
Inventor
도모유키 이가와
신야 이시이
아츠히코 마에다
미카 사쿠라이
데츠오 고지마
다츠히코 다치바나
히로타케 시라이와
히로유키 츠노다
요시노부 히구치
Original Assignee
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 추가이 세이야쿠 가부시키가이샤 filed Critical 추가이 세이야쿠 가부시키가이샤
Publication of KR20110139734A publication Critical patent/KR20110139734A/ko
Application granted granted Critical
Publication of KR101314880B1 publication Critical patent/KR101314880B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020117024354A 2009-03-19 2010-03-19 관절류머티즘 치료제 Active KR101314880B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2009-067358 2009-03-19
JP2009067358 2009-03-19
PCT/JP2010/054763 WO2010107108A1 (ja) 2009-03-19 2010-03-19 関節リウマチ治療剤

Publications (2)

Publication Number Publication Date
KR20110139734A KR20110139734A (ko) 2011-12-29
KR101314880B1 true KR101314880B1 (ko) 2013-10-04

Family

ID=42739764

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117024354A Active KR101314880B1 (ko) 2009-03-19 2010-03-19 관절류머티즘 치료제

Country Status (5)

Country Link
JP (2) JP4809930B2 (enExample)
KR (1) KR101314880B1 (enExample)
RU (1) RU2524152C2 (enExample)
TW (1) TWI457134B (enExample)
WO (1) WO2010107108A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
MX2009007830A (es) 2007-01-23 2009-10-07 Univ Shinshu Inhibidor de rechazo cronico.
TW201503898A (zh) 2008-06-05 2015-02-01 Chugai Pharmaceutical Co Ltd 神經浸潤抑制劑
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
RS63800B1 (sr) 2010-05-28 2022-12-30 Chugai Pharmaceutical Co Ltd Poboljšanje antitumorskog odgovora t ćelije
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
EP3009518B1 (en) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
TWI759261B (zh) 2015-02-27 2022-04-01 日商中外製藥股份有限公司 Ｉｌ－６受體抗體用於製備醫藥組成物的用途
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019078344A1 (ja) 2017-10-20 2019-04-25 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
JPWO2020202839A1 (enExample) 2019-03-29 2020-10-08
AU2020259884A1 (en) 2019-04-17 2021-10-07 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
US12558423B2 (en) 2020-05-29 2026-02-24 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation
CN117320749A (zh) 2021-03-12 2023-12-29 中外制药株式会社 用于治疗或预防重症肌无力的药物组合物
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL182089B1 (en) * 1994-10-21 2001-11-30 Chugai Pharmaceutical Co Ltd Pharmaceutic compositions for treating diseases caused by production of il-6
RU2481356C2 (ru) * 2004-12-28 2013-05-10 Иннейт Фарма Моноклональные антитела против nkg2a
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
RU2505603C2 (ru) * 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
ES2687808T3 (es) * 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
TW201920257A (zh) * 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008020079A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling

Also Published As

Publication number Publication date
JP4809930B2 (ja) 2011-11-09
JP2011219478A (ja) 2011-11-04
TWI457134B (zh) 2014-10-21
RU2524152C2 (ru) 2014-07-27
JPWO2010107108A1 (ja) 2012-09-20
RU2011142183A (ru) 2013-04-27
KR20110139734A (ko) 2011-12-29
WO2010107108A1 (ja) 2010-09-23
TW201034685A (en) 2010-10-01

Similar Documents

Publication Publication Date Title
RU2524152C2 (ru) Средство для лечения ревматоидного артрита
US20240270856A1 (en) Cancer metastasis inhibitor
CA2648644C (en) Muscle regeneration promoter
JP6952454B2 (ja) 抗腫瘍ｔ細胞応答増強剤
CN100556450C (zh) Il-18抑制剂在治疗或预防脓毒症中的应用
RU2490025C2 (ru) Терапевтические средства, используемые против реакции трансплантат против хозяина, содержащие в качестве активного ингредиента ингибитор рецептора интерлейкина-6
TWI528973B (zh) Nerve infiltration inhibitor
KR101239051B1 (ko) 심장질환 치료제
EP1210425B1 (en) Baff receptor (bcma), an immunoregulatory agent
CA2595786C (en) Compositions and methods for treating fibrotic disorders
KR101044180B1 (ko) 개량된 항체분자
AU2009203080B2 (en) Methods for Modulating an Inflammatory Response
US9394362B2 (en) IL-21 antibodies and methods of making or using the antibodies
JP4744763B2 (ja) Ｉｌ−１８阻害剤の用途
BRPI0609762A2 (pt) uso de um agente que reduza o nìvel de il-21 e/ou il-21r, e, método para identificar um composto para tratar, melhorar ou prevenir a fibrose ou um distúrbio associado com a fibrose em um indivìduo
JP2005516907A (ja) 霊長類ｉｆｎ−ガンマ結合分子の使用
JP2010095445A (ja) Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
Simant et al. Interleukin-6, a major player of cytokine storm in COVID-19 and its alleviation by therapeutic antibodies
Yao et al. Sonelokimab. Interleukin-17A and-F nanobody, Treatment of moderate to severe psoriasis, Treatment of hidradenitis suppurativa
JP2010116338A (ja) 同一抗原に特異的に結合する複数の抗体の混合物もしくは複数の抗原結合部位を有する抗体
Gonzalez-Gonzalez et al. Secukinumab
EA046818B1 (ru) Интерферон-ассоциированные антигенсвязывающие белки для лечения инфекции, вызванной вирусом гепатита в

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111017

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120109

Comment text: Request for Examination of Application

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20130730

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20130927

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20130927

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20160919

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20160919

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210917

Start annual number: 9

End annual number: 9